The treatment of ankylosing spondylitis.
Ankylosing spondylitis is an inflammatory disorder affecting the axial skeleton and periphery. Symptoms can often be debilitating. Current therapy for the disease include physical therapy, non-steroidal anti-inflammatory drugs (NSAIDS, anti-rheumatic disease modifying drugs (DMARDS), and the newly developed biologic agents targeting tumor necrosis factor alpha (TNF-alpha). This paper will provide a comprehensive review of these treatments which focusing on evidence based medicine for the daily clinical practice of rheumatology.
Scalapino
K J
KJ
Division of Rheumatology, The University of California San Francisco, 533 Parnassus Avenue, Box 0633, Room U383, San Francisco, CA 94143, USA.
Davis
J C
JC
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000627:therapeutic use; D000077268:Pamidronate; D026741:Physical Therapy Modalities; D013167:Spondylitis, Ankylosing / Q000628:therapy*; D013792:Thalidomide / Q000378:metabolism / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000929:Antidepressive Agents, Tricyclic; D018501:Antirheumatic Agents; D004164:Diphosphonates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; D000077268:Pamidronate